Diovol (Aluminum Hydroxide, Magnesium Hydroxide, Simethicone) is an antacid commonly used to provide supportive relief for symptomatic discomfort arising from symptoms related to heightened physiological activity. Its main uses are to help address heartburn, sour stomach, acid indigestion, and the symptoms referred to as gas. The medication is applied in situations involving certain distressing symptoms that may interfere with daily comfort and stability.

---

Easing Acute Gastrointestinal Distress

Diovol is often applied to manage sudden or intensified clusters of digestive symptoms. It offers short-term symptomatic assistance and may support general well-being during phases of heightened discomfort. It is considered relevant in conditions involving episodic or fluctuating manifestations, such as occasional indigestion or dyspepsia. It is relevant for managing symptoms that interfere with daily comfort.

The medicine supports patients during episodes of heightened discomfort by easing the overall symptom load.

Diovol contributes to improved comfort during periods of heightened symptoms and provides supportive relief when symptoms interfere with routine activities. It is relevant when supportive symptom management is appropriate for easing symptom intensity.

Quick Fact: Relevant for Acid Indigestion Symptoms

Regulatory References

1. FDA-Authorized Drug Label on DailyMed

Diovol is an over-the-counter medicine containing aluminum hydroxide, magnesium hydroxide, and simethicone. Official eligibility rules define specific populations who should not use this product, primarily due to risks of mineral accumulation or known allergy.

Eligibility Restrictions

Eligibility Status	Population/Condition	Regulatory Basis
Contraindicated	Known hypersensitivity or allergy to any component.	Formal Restriction
Contraindicated	Severe renal impairment or kidney failure (due to risks of aluminum and magnesium accumulation).	Systemic Toxicity Risk
Use Restricted	Children under the age specified on the product label (typically under 12 years old).	Safety Not Established

Special Consideration Required

Patients with certain pre-existing conditions should consult a healthcare professional before use, as the medicine may affect their condition or absorption of other drugs. These include individuals with kidney problems, a history of intestinal obstruction, low phosphate levels, or frequent alcohol use. Chronic daily use for more than two weeks is not recommended without medical advice. Women who are pregnant or breastfeeding should also seek guidance before taking this medication.

Interactions with other medicines and products

Diovol, a non-systemic antacid containing Aluminum Hydroxide and Magnesium Hydroxide, interacts with numerous oral medications primarily by pharmacokinetic mechanisms that reduce drug absorption. This effect is driven by the metal cations ( Al^3+ and Mg^2+) forming insoluble complexes (chelation) and by the resulting increase in gastric pH.

Official Interaction Classifications

Classification	Interacting Agents and Outcome
Contraindicated Combinations	Pazopanib and Raltegravir are prohibited due to critical reductions in their plasma concentrations. Co-administration with Sodium Polystyrene Sulfonate is restricted due to the risk of intestinal obstruction.
Exposure-Modifying Substances	Fluoroquinolone Antibiotics, Tetracycline Antibiotics, Levothyroxine, and Bisphosphonates exhibit significantly reduced systemic exposure.

Regulatory Constraints

The most frequent constraint in regulatory labeling is the mandatory timing rule. To mitigate the reduced absorption of interacting medicines, administration of Diovol must be separated by at least 2 hours from most other oral medications. Furthermore, the Aluminum Hydroxide component carries an interaction restriction concerning citrate-containing products (e.g., specific juices or effervescent drugs). This combination significantly increases serum aluminum levels, posing a toxicity risk, particularly for patients with renal impairment, where accumulation is already a concern. The overall interaction structure requires strict adherence to these time-separation rules and combination prohibitions.

Diovol's mechanism of action involves a dual-component system for modulating processes within the gastrointestinal tract.

The antacid component, consisting of Aluminum Hydroxide ( Al( OH)3) and Magnesium Hydroxide ( Mg( OH)2), targets the primary biological mechanism of neutralization. These salts react with excess gastric hydrochloric acid (HCl) to consume protons (H^+) and elevate the gastric pH. The resulting chemical products are the inert salts Aluminum Chloride ( AlCl3), Magnesium Chloride ( MgCl2), and water ( H2 O).

The second component is Simethicone, a surface-active polymer. Simethicone acts by significantly decreasing the surface tension of intraluminal gas bubbles. This physical interaction promotes the coalescence of smaller, dispersed bubbles into larger bubbles, a physiological change that facilitates their expulsion. The combined action of the two components thus exerts concurrent modulation of gastric acidity and gas dynamics.

Official Administration Guidelines

Diovol (Aluminum Hydroxide, Magnesium Hydroxide, Simethicone) is an orally administered combination medicine. Instructions for its correct use are strictly governed by official regulatory documentation, defining the appropriate dosage and administration method.

---

Dosing and Administration Schedule

The medicine is designed for as-needed (PRN) use. The official directions specify the following guidelines for adults and children 12 years and older:

Administration Scope	Official Guidance
Route of Administration	Oral only (Suspension or Chewable Tablet)
Adult Single Dose	10 mL to 30 mL of the oral suspension, or 2 to 4 chewable tablets.
Timing	Administer between meals, at bedtime, or as otherwise directed.
Frequency	Up to four times a day (q.i.d.).

---

Procedural and Course Constraints

Adherence to preparation steps and time limitations is required for proper administration:

• Preparation: The oral suspension must be shaken well before each dose is measured, typically with a specialized device. Chewable tablets must be chewed thoroughly before swallowing.
• Maximum Dose: Do not exceed the maximum daily limit (e.g., typically 60 mL of high-strength suspension or 12 tablets) in a 24-hour period.
• Duration: Administration at maximum dosage is intended for short-term use and should not exceed two consecutive weeks without explicit medical guidance.
• Age Restriction: Use of this combination product in children under 12 years of age is only permitted after consultation with a physician.

These official instructions define a standardized protocol for use, requiring specific preparation of the dosage form and imposing strict limits on both the frequency and total duration of administration.

Research evidence / Overview of studies for Diovol

This section summarizes the types of scientific studies that have explored the use of the medicine's components, based on reports from regulatory bodies and peer-reviewed literature. It focuses only on what the research has examined and what remains uncertain, without providing guidance on use or expected outcomes.

---

Evidence for Symptomatic Relief of Hyperacidity (Heartburn and Indigestion)

Research has examined the antacid components—Aluminum Hydroxide and Magnesium Hydroxide—primarily through pharmacodynamic studies and short-term clinical trials. Pharmacodynamic research was used to measure the chemical ability of the salts to neutralize acid, referred to as Acid Neutralizing Capacity (ANC). These studies included measurements of the pH level inside the stomach to characterize chemical change following administration.

Studies involving people have monitored outcomes related to physiological imbalance, using patient-reported outcomes describing perceived discomfort for heartburn. Research highlights findings describing patterns observed in the studies related to changes in acute symptom intensity; however, data show patterns related to symptomatic changes that were generally short-lived, a duration consistent with non-systemic treatments.

Evidence for Symptomatic Relief of Excess Gas (Bloating and Pressure)

The antiflatulent component, Simethicone, was evaluated in Randomized Controlled Trials (RCTs) and systematic reviews. These studies were applied in research exploring how symptoms change over time in adults dealing with conditions characterized by fluctuating or episodic manifestations of gas and bloating.

In laboratory and visualization settings, studies observed that the antiflatulent component was associated with the physical alteration of the surface tension of gas bubbles. Clinical trials, however, reported that findings were mixed regarding how reliably patient-reported outcomes describing perceived discomfort for gas and bloating changed. The variability and subjective nature of patient-reported "gas" symptoms make it challenging to establish consistent, measurable outcomes across all trials.

What Research Gaps and Uncertainties Remain

The follow-up duration of research for this class of medicine is typically aligned with the acute use context for episodic symptom patterns. For this reason, long-term effects are not fully established, and there is limited information for long-term outcomes beyond the few weeks typical of over-the-counter (OTC) guidance.

Data for certain groups remain insufficient, including pregnant individuals and children under 12, meaning that results apply only to the populations studied in the trials. The added value of the fixed combination versus using the antacid and antiflatulent components separately is still uncertain, as comprehensive comparative evidence is lacking.

Key Studies & References

1. Aluminum Hydroxide, Magnesium Hydroxide, Simethicone Oral Suspension - DailyMed Label
2. Pharmacodynamics and Pharmacokinetics of Antacids in the Treatment of Functional Dyspepsia and Gastroesophageal Reflux Disease

Common questions about Diovol (FAQ)

---

Q: How quickly is Diovol supposed to start working after you take it?

Official product descriptions indicate that this medicine is formulated to provide rapid relief from excess stomach acid. Research has noted that the acid-neutralizing effects may be noticeable within a few minutes of administration.

---

Q: Why is Diovol sometimes taken before meals?

Official labeling specifies that the medicine may be administered at certain times, such as between meals or at bedtime. Taking the product at these times is generally intended to provide symptomatic relief during periods when symptoms commonly occur.

---

Q: Are there any common minerals or supplements that interact with Diovol?

Yes, official documents indicate that the medicine can interact with certain oral mineral preparations. For example, the aluminum component can bind to phosphate in the gut, making phosphate supplements (such as potassium phosphate) one group that may interact.

---

Q: Is the liquid form of Diovol different in strength from the tablet form?

The oral suspension and the chewable tablets have distinct dosage instructions that are detailed on the specific product packaging. This difference in measurement is due to the varying concentrations of active ingredients between the liquid and tablet formulations.

---

Q: Is it true that Diovol can interact with heart medications?

Official drug interaction information includes certain heart medications, such as digoxin, among the drugs whose systemic absorption may be reduced by the components of this product. Official regulatory guidelines advise separating the administration of Diovol from other oral medicines by at least two hours.

---

Q: Why might a doctor prescribe Diovol over other over-the-counter options?

The medicine is a combination formulation that includes two different antacids and an antiflatulent agent. This specific combination is often used to help balance potential side effects like diarrhea and constipation while also addressing gas and bloating.

---

Q: Can you take Diovol with other antacid products?

Official information notes that the components of this medicine (aluminum and magnesium) are sometimes used in combination with single-salt antacids. This is occasionally done to help balance their respective side effects, such as managing potential diarrhea or constipation.

---

Q: Is Diovol the same kind of medicine as Gaviscon?

No, they belong to different regulatory categories. Diovol is primarily a combination antacid and antiflatulent. Products like Gaviscon often contain an alginate component that works differently by creating a protective physical barrier, or 'raft,' on top of the stomach contents.

---

Q: What happens if you miss a dose of Diovol?

Regulatory guidance describes a standard protocol for missed doses: if a dose is missed, it may be taken as soon as it is remembered. However, if it is near the time for the next scheduled dose, the instruction is typically to skip the missed dose and resume the regular schedule.

---

Q: Do official documents mention any potential for addiction to Diovol?

Diovol is classified as a non-systemic, over-the-counter medicine. It is not listed as a controlled substance in official documentation, and the labels do not include warnings regarding abuse or dependence.

---

Q: Is Diovol used for stomach ulcers?

Official information describes that this medicine is used for the symptomatic relief of heartburn and indigestion, and its components are sometimes mentioned in the context of preventing or assisting with ulcers in certain regulatory documents.

---

Q: Can people with diabetes use Diovol?

Official information notes that some liquid or tablet formulations of this medicine may contain sugar or non-sugar sweeteners, which may be relevant for individuals with diabetes. The official guidance requires that individuals with pre-existing conditions seek specific guidance.

---

Q: Does Diovol contain any sweeteners or artificial colors?

Official documents for certain formulations note the presence of ingredients such as sugar or aspartame (a sweetener). Excipient information is product-specific, and the full ingredient list is available for consumers to review on their purchased product.

---

Q: What official body approved Diovol for use?

The use and sale of Diovol are authorized by national regulatory bodies that oversee drug products. For example, in certain jurisdictions, its approval is overseen by an agency such as Health Canada.

Storage Conditions

Diovol must be stored strictly according to regulatory guidelines to maintain its stability. The product requires storage at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). The medicine must be kept in its original container with the cap tightly closed when not in use. It is mandatory to protect the product from environmental extremes: do not freeze the suspension, and shield it from excessive heat, direct sunlight, and moisture. Do not use the medicine past the expiration date printed on the packaging.

Disposal and Child Safety

All medicines, including Diovol, must be stored out of the sight and reach of children to prevent accidental ingestion, as mandated by regulatory authorities. For disposal of unused or expired product, the preferred method is to use an authorized drug take-back program. If a take-back program is unavailable, the medicine may be discarded in the household trash after mixing it with an undesirable substance, such as dirt or used coffee grounds, and placing the mixture in a sealed container.